Comparison of efficacy and safety of escitalopram and vilazodone in major depressive disorder
Journal Title: National Journal of Physiology, Pharmacy and Pharmacology - Year 2018, Vol 8, Issue 8
Abstract
Background: Major depressive disorder (MDD) is a worldwide prevalent psychiatric ailment associated with significant morbidity and mortality. Escitalopram is an effective selective serotonin reuptake inhibitor (SSRI), and vilazodone is a newer SSRI and partial serotonin receptor agonist approved for MDD. Aims and Objectives: The aim was to evaluate and compare the efficacy and safety of escitalopram and vilazodone in patients of MDD. Materials and Methods: The present, randomized study was conducted in a tertiary care teaching institute, and 50 patients between 18 and 55 years of either sex diagnosed with MDD based on Diagnostic and Statistical Manual of Mental Disorders Fifth Edition criteria were included in the study. Patients were assigned randomly into two groups to receive orally either escitalopram (10 mg) or vilazodone (20 mg) and baseline scores of Hamilton Anxiety Scale (HAM–A) and Hamilton Depression Rating Scale (HAM-D) were recorded. These were then assessed at 6 weeks for post-drug scores and compared with baseline using Mann–Whitney and Wilcoxon signed-rank test statistical analytic method. Intergroup comparison was also done. Results: Average age of the patients taken was 39.74 ± 8.6 years with a male:female ratio of 19:31. The HAM-D score was significantly lowered by both escitalopram and vilazodone (P < 0.0001). HAM-A score was also similarly lowered by escitalopram (P < 0.0001) and vilazodone (P < 0.0001). On intergroup comparison, escitalopram was found to cause more lowering of HAM-D score and HAM-A score than vilazodone (P < 0.0001). Biochemical profile (blood sugar, serum urea, creatinine, hemoglobin, and total leukocyte counts) was not altered with either of the drugs over 6 weeks. No significant adverse drug reactions were noted with the drugs. Conclusion: Both drugs are effective in decreasing depression and anxiety scores in patients of MDD. On comparison, escitalopram was found better than vilazodone.
Authors and Affiliations
Palvi Kudyar, Brij Mohan Gupta, Vijay Khajuria, Rakesh Banal
Keywords
Related Articles
- EP ID EP491235
- DOI 10.5455/njppp.2018.8.0412120042018
- Views 71
- Downloads 0
Autonomic cardiovascular regulation in Parkinson’s disease by head-up tilt test - A cross-sectional study
Background: Autonomic failure is an integral component of Parkinson’s disease (PD), and orthostatic hypotension (OH) is commonly observed in advanced cases of PD. OH may be the result of underlying cardiovascular autonom...
Comparison of sympathetic nervous activity among male and female patients of bronchial asthma
Background: There is substantial evidence of gender difference in the functioning of the autonomic nervous system. It is suggested that men have higher sympathetic tone and women have higher parasympathetic autono...
A randomized open-label study to compare the effects of amlodipine and cilnidipine on heart rate and proteinuria in subjects with hypertension with proteinuria
Background: Calcium channel blockers (CCBs) are a commonly used class of drugs for the treatment of hypertension. Cilnidipine is a novel CCB with a dual L/N-type CCB property, thus favoring additional renal and cardiovas...
Interarm blood pressure difference: Magnitude and prevalence in healthy adults
Background: Hypertension is one of the major preventable causes of premature morbidity and mortality worldwide. Measurement of blood pressure (BP) is the most common investigation performed in primary care setting to man...
Effect of loud music and active telephonic conversation on simple visual reaction time
Background: In India, there is at least one death for every 4 min due to road traffic accidents (RTA’s) (1.37, 423 deaths in a year), of which 77.5% are due to fault of drivers. Many vehicles are equipped with high volum...